Abstract: The disclosure relates to systems and methods for performing high performance liquid chromatography (HPLC) on a liquid sample. The methods include automatically, using a computer, controlling a liquid sample including a plurality of components to flow through a first flow path in a system for HPLC. Flowing through the first flow path includes flowing the liquid sample through a capture column. The capture column is capable of trapping at least some of the components of the liquid sample. The method includes automatically, using the computer, controlling a solvent to flow through a second flow path in the system for HPLC. Flowing through the second flow path includes flowing the solvent through the capture column to elute the trapped components from the capture column; flowing the solvent and eluted components through an analysis column capable of separating the eluted components; and flowing the separated components to a detector.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: A vented filter is placed at the HPLC (High Performance Liquid Chromatography) loop entry port of an HPLC injector valve. The vented filter prevents the push gas used to deliver the crude radiolabeled product from over-pushing the liquid to waste. Push gas is vented off when the entire crude liquid product has passed through the vented filter and been loaded onto the HPLC loop.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: A vented filter is placed at the HPLC (High Performance Liquid Chromatography) loop entry port of an HPLC injector valve. The vented filter prevents the push gas used to deliver the crude radiolabeled product from over-pushing the liquid to waste. Push gas is vented off when the entire crude liquid product has passed through the vented filter and been loaded onto the HPLC loop.

Abstract: The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.

Abstract: The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography.

Abstract: A beta detector assembly for use in the synthesis and analysis of radiopharmaceuticals, such as in microfluidic radiochromatography. The beta detector assembly includes a base, preferably fabricated from glass so as to take advantage of electroosmotic flow, that serves as the body of the beta detector assembly. A microfluidic channel passes through the length of the base. A solid-state charge particle detector, for detecting beta particles, is provided and is positioned with respect to the base so as to receive beta particles. A portion of the base is disposed between the microfluidic channel and the solid-state charge particle detector and has a thickness that is selected to substantially allow transmission of beta particles there thru for detection by the charge particle detector. In one embodiment, the base is fabricated of glass. In another embodiment, the base is fabricated of silicon such that the base and the solid-state charge particle detector are integral.

Abstract: The invention provides a method and apparatus for preparation of radiochemicals wherein the reaction that couples the radioactive isotope to the reactive precursor to form a positron-emitting molecular imaging probe is performed in a microfluidic environment.